axlr_logo-2022_HD_bleudeprusseaxlr_logo-2022_HD_bleudeprusseaxlr_logo-2022_HD_bleudeprusseaxlr_logo-2022_HD_bleudeprusse

  • SATT AxLR
    • SATT AxLR
    • Governance
    • Services for companies
    • Annual reports
  • Assisting you
    • Researchers
      • Call-for-projects
    • Companies
    • Startups
    • Practical guide
  • Technology offerings
    • Invest
      • In our technologies
      • In our startups
    • Technologies
    • Startups
    • AxLR TV
  • Working with AxLR
    • Purchasing & public procurement
    • Join us
    • Our startups are hiring
  • Media
    • News
    • Agenda
    • Press kit
    • Communication kit
  • Contact
English
  • French
✕
  • Home
  • DIAG2TEC – MYELODIAG
EPIDROP
6 May 2019
EMOSIS
6 May 2019

DIAG2TEC – MYELODIAG

DIAG2TEC - MYELODIAG

Predicting the treatment response of patients with multiple myeloma

Startup

IP

  • Patent

Establishment(s)

  • University of Montpellier
  • Inserm
  • CNRS
  • EPHE

Laboratory(ies)

  • Mécanismes moléculaires dans les démences neurodégénératives (MMDN)

Keywords

  • Huntington
  • Neurodegenerative diseases

Context

Multiple myeloma is the second most common malignant blood disease, after lymphoma. It is characterized by the accumulation of a clone of tumor plasma cells in blood marrow. Current treatments are not able to avoid relapses, which generally end up with the patient's death. This disease varies greatly among different people, and patients' response to treatment is extremely heterogeneous. It is therefore essential to prepare new therapeutic strategies. New treatments of multiple myeloma are currently being developed to meet this challenge

Benefits

The innovation proposed by Myelodiag is based on genetic expression data. The solution involves identifying biomarkers that can predict the sensitivity of tumor plasma cells to therapeutic agents. The goal is to develop therapeutic orientation tests and be able to offer personalized treatment for patients with multiple myeloma, and thus improve treatment results.

Applications

Theranostics tests, in-vitro medical diagnostic equipment, biomarkers

START-UP I Oncology – Therapeutic diagnostic tool

Share
4

Related posts

8 September 2021

StabCFTR


En savoir +
6 July 2021

HTLV-1


En savoir +
23 June 2021

GEOSOTECH


En savoir +
© 2023, AxLR - SATT Occitanie Méditerranée. All rights reserved. | Legal terms & Privacy policy
English
  • English
  • French